Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria

ABSTRACT A major challenge facing malaria vaccine development programs is identifying efficacious combinations of antigens. To date, merozoite surface protein 1 (MSP1) is regarded as the leading asexual vaccine candidate. Apical membrane antigen 1 (AMA1) has been identified as another leading candidate for an asexual malaria vaccine, but without any direct in vivo evidence that a recombinant form of Plasmodium falciparum AMA1 would have efficacy. We evaluated the efficacy of a form of P. falciparum AMA1, produced in Pichia pastoris, by vaccinating Aotus vociferans monkeys and then challenging them with P. falciparum parasites. Significant protection from this otherwise lethal challenge with P. falciparum was observed. Five of six animals had delayed patency; two of these remained subpatent for the course of the infection, and two controlled parasite growth at <0.75% of red blood cells parasitized. The protection induced by AMA1 was superior to that obtained with a form of MSP1 used in the same trial. The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to the protection obtained with AMA1 alone, although the immunity generated appeared to operate against both vaccine components.

[1]  A. Saul,et al.  In Vitro Studies with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 (AMA1): Production and Activity of an AMA1 Vaccine and Generation of a Multiallelic Response , 2002, Infection and Immunity.

[2]  A. Kelso,et al.  The Mechanism and Significance of Deletion of Parasite-specific CD4+ T Cells in Malaria Infection , 2002, The Journal of experimental medicine.

[3]  A. Saul,et al.  Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. , 2002, The Journal of infectious diseases.

[4]  D. Kaslow,et al.  A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Anders,et al.  Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.

[6]  D. Kaslow,et al.  Efficacy of Two Alternate Vaccines Based on Plasmodium falciparum Merozoite Surface Protein 1 in anAotus Challenge Trial , 2001, Infection and Immunity.

[7]  D. Kaslow,et al.  Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes , 2000, Infection and Immunity.

[8]  Huji Xu,et al.  CD4+ T Cells Acting Independently of Antibody Contribute to Protective Immunity to Plasmodium chabaudi Infection After Apical Membrane Antigen 1 Immunization1 , 2000, The Journal of Immunology.

[9]  S. Hoffman,et al.  Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. , 2000, The American journal of tropical medicine and hygiene.

[10]  A. Thomas,et al.  Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoeliiYM Blood-Stage Infection , 2000, Infection and Immunity.

[11]  M. Blackman,et al.  Immunogenicity and Efficacy in Aotus Monkeys of Four Recombinant Plasmodium falciparum Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1 , 2000, Infection and Immunity.

[12]  M. Blackman,et al.  Vaccine Efficacy of Recombinant Plasmodium falciparumMerozoite Surface Protein 1 in Malaria-Naive, -Exposed, and/or -Rechallenged Aotus vociferans Monkeys , 2000, Infection and Immunity.

[13]  A. Taylor-Robinson,et al.  A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection , 1999, Immunological reviews.

[14]  R. Anders,et al.  A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. , 1997, Journal of immunology.

[15]  Q. Cheng,et al.  Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. , 1997, The American journal of tropical medicine and hygiene.

[16]  R. Anders,et al.  Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes , 1996, Infection and immunity.

[17]  P. Barr,et al.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria , 1996, Infection and immunity.

[18]  D. Kaslow,et al.  Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys , 1995, Molecular medicine.

[19]  R. Coppel,et al.  Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. , 1994, The American journal of tropical medicine and hygiene.

[20]  P. Caspers,et al.  Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection , 1992, Infection and immunity.

[21]  A. Waters,et al.  Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen , 1988, Parasite immunology.

[22]  R. Anders,et al.  CD4 T Cells Acting Independently of Antibody Contribute to Protective Immunity to Plasmodium chabaudi Infection After Apical Membrane Antigen 1 Immunization , 2000 .

[23]  R. Anders,et al.  Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. , 1998, Vaccine.